Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm

NCT ID: NCT04551014

Last Updated: 2022-09-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

158 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-16

Study Completion Date

2021-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The focus of the study is to evaluate impact of submucosal injection of EverLift in achieving complete resection during polypectomy of polyps 4-9mm during colonoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The details of the proposed study are as follows:

1. Experimental group: using EverLift submucosal injection for polyps 4-9mm of the colon
2. Control group: not using EverLift submucosal injection for polyps 4-9mm of the colon
3. Methods:

1. Colonoscopy will be performed in the same standard of care manner as if no study was taking place.
2. If polyps 4-9mm are identified, the endoscopist is randomized to performing polypectomy with or without submucosal injection of EverLift.
3. After removal of the polypectomy, two biopsies are performed at the margin of the polypectomy site to identify residual lesion.
4. The polyp as well as well as the two biopsies are reviewed by a pathologist.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colo-rectal Cancer Polyp of Colon Adenomatous Polyp of Colon

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With EverLift

Polypectomy performed for polyps 4-9mm with submucosal injection of EverLift.

Group Type EXPERIMENTAL

Use of EverLift

Intervention Type DEVICE

Use of EverLift for submucosal injection prior to polypectomy

Without EverLift

Polypectomy performed for polyps 4-9mm without submucosal injection of EverLift.

Group Type EXPERIMENTAL

Without use of EverLift

Intervention Type DEVICE

Without use of EverLift for submucosal injection prior to polypectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Use of EverLift

Use of EverLift for submucosal injection prior to polypectomy

Intervention Type DEVICE

Without use of EverLift

Without use of EverLift for submucosal injection prior to polypectomy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients 18 years or older
* Polyps 4-9mm

Exclusion Criteria

* Pregnant
* Inflammatory bowel disease
* Polyposis syndromes
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stanford University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shai Friedland

Professor in Gastroenterology & Hepatology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shai Friedland, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Veterans Affairs Palo Alto Health Care System

Palo Alto, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15766-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.